Scancell is a clinical-stage immuno-oncology company which was founded in 1997 on research led by Professor Lindy Durrant at the University of Nottingham. The Company is operating at the forefront of immuno-oncology, an exciting field of cancer research which involves the development of immunotherapies to harness the body’s ability to generate and sustain an effective immune response against cancer.

The cancer immunotherapy market is one of the most rapidly growing markets within the biopharmaceutical industry, estimated to be worth USD100 billion by the year 2022. Immunotherapies are being evaluated in most cancer indications and their unrivalled efficacy and relatively low toxicity profile compared to chemotherapy is already leading to paradigm shifts in the treatment of many cancers. However, tumours often successfully evade the body’s own natural defence mechanism, the immune system, and not all patients are able to respond to checkpoint inhibitor-based immunotherapies. Therapeutic vaccines therefore have the potential to improve the proportion of patients who are able to benefit by initiating immune responses that convert unresponsive tumours, or so-called “cold” tumours, into “hot” ones.

The commercial potential of Scancell’s products will be defined by clinical data, either as monotherapies or in combination with checkpoint inhibitors, designed to provide increased and durable responses in patients without compromising safety and to address the unmet needs in hard to treat cancers. Scancell’s three technology platforms, ImmunoBody®, Moditope® and AvidiMab™, each offers a unique approach to cancer therapy to address all of these criteria.

As the COVID-19 pandemic has unfolded, Scancell has evaluated how it can best contribute its expertise and resources to help in the global response. Vaccines are the long-term solution and the company believes its combined high avidity T cell and neutralising antibody approach has the potential to produce a second-generation vaccine that will generate an effective and durable immune response to COVID-19. Scancell has therefore initiated its COVIDITY programme to develop a COVID-19 vaccine in collaboration with scientists at the University of Nottingham and Nottingham Trent University.

Board of Directors

Dr John Chiplin
Professor Lindy Durrant
(Chief Executive Officer, Chief Scientific Officer)
Dr Sally Adams
(Chief Development Officer)
Dr Richard Goodfellow
(Non-Executive Director)
Martin Diggle
(Non-Executive Director)
Dr Ursula Ney
(Non-Executive Director)
Susan Clement Davies
(Non-Executive Director)


Professor Lindy Durrant
(Chief Executive Officer, Chief Scientific Officer)
Dr Sally Adams
(Chief Development Officer)
Dr Gillies O'Bryan-Tear
(Chief Medical Officer)
Keith Green
(Director of Finance & Admin, Company Secretary)
Dr Robert Miller
(Medical Director)
Dr Samantha Paston
(Head of Translational Research)
Dr Adrian Parry
(Head of Manufacturing)
Akua Asare
(Head of Quality)
Fayaz Master
(Head of Clinical Operations)

Clinical Advisory Board

Chairman, Professor Robert Coleman MBBS, MD, FRCP, FRCPE
Professor Christian Ottensmeier MD, PhD, FRCP
Professor Poulam Patel MD, PhD, MBBS, FRCP
Professor Iain McNeish MD, PhD, FRCP
Professor David Miles MB, BS, BSc, FRCP, MD
Professor Stephen Chan DM, FRCP, FRCR



Collaboration on Moditope T cell receptor therapeutics

ISA Pharmaceuticals

Agreement to supply Amplivant® adjuvant for Modi-1

Ichor Medical Systems

Use of TriGrid™ Delivery System

University of Nottingham

Licensing of anti-glycan monoclonal antibodies COVID-19 vaccine

Nottingham Trent University

COVID-19 vaccine